A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. Issue 1 (28th December 2017) - Liu, Chen‐Hua
Abstract: Background and Aims: The diagnostic accuracy of a novel serological panel (BioFibroScore®) to predict hepatic fibrosis in patients with chronic hepatitis C virus (HCV) infection is unknown. Methods: Three markers of BioFibroScore, including urokinase plasminogen activator, matrix metalloproteinase‐9, and beta‐2 microglobulin, were retrospectively evaluated in 635 HCV‐infected patients who received percutaneous liver biopsy and FibroScan®. The formula of BioFibroScore to predict the severity of hepatic fibrosis was developed by adaptive boosting algorithm. The diagnostic accuracy of hepatic fibrosis was assessed both for BioFibroScore and FibroScan, taking METAVIR fibrosis score as the reference standard. Results: Urokinase plasminogen activator and beta‐2 microglobulin were positively and matrix metalloproteinase‐9 was negatively associated with the severity of hepatic fibrosis. Thirty‐five (5.5%) patients had failed FibroScan assessment. By adaptive boosting model for BioFibroScore and the established reference ranges for FibroScan, 85.7% and 89.0% of the patients had an identical result for F0‐1, F2, F3, and F4, as compared with liver biopsy. The concordance rate between BioFibroScore and FibroScan was 80.7%. BioFibroScore overestimated and underestimated the stage of hepatic fibrosis in 8.3% and 6.0% patients, and most patients had one stage error. Among patients with failed FibroScan assessment, 82.9% of them were correctly diagnosed by BioFibroScore. Bootstrap analysis for BioFibroScore showed the diagnostic accuracy was 80.9–88.4%. Conclusions: BioFibroScore is accurate to assess the stage of hepatic fibrosis in HCV‐infected patients. Applying this noninvasive test can substantially reduce the need for invasive liver biopsy and can play a role for fibrosis evaluation when FibroScan assessment was unavailable or unreliable.